ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
요폐 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.1%의 성장률(CAGR)로 52억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 요폐 유병률 증가, 수술 후 요폐 사례 증가, 요실금(UI) 발생률 증가, 조기 진단 및 조기 치료의 이점에 대한 인식 증가, 전립선 비대증 유병률 증가 등의 요인에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 표적 약물전달 시스템, 약물 제형, 인공지능 및 머신러닝, 원격의료 및 원격 모니터링, 혁신적 솔루션의 발전 등이 있습니다.
비뇨기 질환의 유병률 증가는 요폐 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 배뇨장애는 비뇨기 계통에 영향을 미치는 질환으로 배뇨곤란, 통증, 요실금, 요폐 등의 문제를 유발합니다. 혈당 상승은 신장과 요로에 손상을 입혀 당뇨병성 신증, 잦은 요로감염(UTI) 등의 증상을 유발할 수 있기 때문입니다. 요폐약은 소변의 흐름을 개선하고, 방광 근육을 이완시키고, 배뇨 곤란과 같은 증상을 완화하여 편안함과 방광 기능을 개선하여 이러한 증상을 관리하는 데 도움이 될 수 있습니다. 예를 들어, 2023년 10월 영국 국민보건서비스(NHS)는 2022/23년 요로감염(UTI)을 주 진단명으로 한 14만 7,285건의 입원을 보고했습니다. 이 중 65세 이상이 56%, 총 입원 건수는 8만 2,392건으로 80-84세가 가장 많았으며, 80-84세가 1만 7,280건으로 가장 많았습니다. 이러한 비뇨기 질환의 유병률 증가가 요폐치료제 시장의 성장을 견인하고 있습니다.
요폐 치료제 시장의 주요 업체들은 환자의 순응도를 높이고 증상을 장기간 완화하기 위해 서방형 정제와 같은 혁신적인 제형 개발에 주력하고 있습니다. 서방형(ER) 정제는 유효성분이 시간이 지남에 따라 서서히 방출되도록 설계되어 혈중 약물 농도를 일정하게 유지하여 즉시 방출 정제와 비교하여 빈번한 투여의 필요성을 줄입니다. 예를 들어, 2024년 4월 인도 제약회사 자이더스 라이프사이언스(Zaidas Life Sciences Limited)는 과민성 방광(OAB) 치료제 미라베글론(Mirabegron)의 제네릭 의약품을 출시하였습니다. 선택적 β3 아드레날린 작용제인 미라베글론은 방광 근육을 이완시켜 절박뇨, 빈뇨, 요실금을 감소시킵니다. 주로 과민성 방광에 사용되지만 과민성 방광과 관련된 요폐 관리에도 도움이 되며, 1일 1회 경구 투여합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 요폐 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 요폐 치료제 시장 : 성장률 분석
세계의 요폐 치료제 시장 실적 : 규모와 성장, 2019-2024
세계의 요폐 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 요폐 치료제 전체 시장(TAM)
제6장 시장 세분화
세계의 요폐 치료제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
알파 차단제
베타 3작용제
항콜린제
외과용 약제
세계의 요폐 치료제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
만성 요폐
수술 후 요폐
신경인성 방광
세계의 요폐 치료제 시장 관리국에 의한 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사제
경피
세계의 요폐 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 요폐 치료제 시장 알파 차단제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
알파 1차단제
알파 2차단제
세계의 요폐 치료제 시장,β3작용제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
선택적β3작용제
세계의 요폐 치료제 시장 항콜린제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항무스카린약
비선택적 항콜린제
세계의 요폐 치료제 시장 수술 약제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
마취제
지혈제
근이완제
항생제 예방
제7장 지역별·국가별 분석
세계의 요폐 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 요폐 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
요폐 치료제 시장 : 경쟁 구도
요폐 치료제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb Company
AstraZeneca PLC
Novartis International AG
GlaxoSmithKline plc
Medtronic plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Teva Pharmaceutical Industries Limited
Boehringer Ingelheim International GmbH
Astellas Pharma Inc.
Sun Pharmaceutical Industries Limited
Aurobindo Pharma Limited
Lupin Limited
Cadila Healthcare Limited
Torrent Pharmaceuticals Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
요폐 치료제 시장 2029 : 새로운 기회를 제공하는 국가
요폐 치료제 시장 2029 : 새로운 기회를 제공하는 부문
요폐 치료제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Urinary retention drugs are medications used to treat conditions where patients experience difficulty emptying the bladder, often by relaxing the bladder muscles or stimulating contractions in the bladder to help urine flow. These drugs are commonly prescribed for conditions such as benign prostatic hyperplasia (BPH) or neurogenic bladder, aiming to improve urinary function and relieve discomfort.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug classes for urinary retention include alpha blockers, beta-3 agonists, anticholinergics, and surgical agents. Alpha blockers are drugs that work by relaxing the bladder and prostate muscles, helping to improve urine flow and alleviate symptoms of BPH. These medications are used for conditions such as chronic urinary retention, postoperative urinary retention, and neurogenic bladder. They can be administered via oral, injectable, or transdermal routes and are prescribed in various settings, including hospitals, home care, specialty clinics, and others.
The urinary retention drug market research report is one of a series of new reports from The Business Research Company that provides urinary retention drug market statistics, including the urinary retention drug industry global market size, regional shares, competitors with the urinary retention drug market share, detailed urinary retention drug market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary retention drug industry. This urinary retention drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The urinary retention drug market size has grown strongly in recent years. It will grow from$3.87 billion in 2024 to $4.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to factors such as a rising aging population, increased healthcare investments, advancements in medical infrastructure, a growing geriatric demographic, a global increase in the elderly population, and a higher prevalence of BPH.
The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to$5.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to factors such as the rising prevalence of urinary retention, an increase in postoperative urinary retention cases, a higher occurrence of urinary incontinence (UI), growing awareness of the benefits of early diagnosis and treatment, and the increasing prevalence of benign prostatic hyperplasia. Key trends in the forecast period include advancements in targeted drug delivery systems, drug formulations, artificial intelligence and machine learning, telemedicine and remote monitoring, as well as innovative solutions.
The growing prevalence of urinary disorders is expected to fuel the expansion of the urinary retention drug market. Urinary disorders are conditions that affect the urinary system, leading to issues such as difficulty urinating, pain, incontinence, or retention. The rise in these disorders is largely due to the increasing incidence of diabetes, as elevated blood sugar levels can damage the kidneys and urinary tract, resulting in conditions such as diabetic nephropathy and frequent urinary tract infections (UTIs). Urinary retention drugs help manage these conditions by improving urine flow, relaxing bladder muscles, and alleviating symptoms such as difficulty urinating, thus enhancing comfort and bladder function. For example, in October 2023, the National Health Service (NHS) in England reported 147,285 hospital admissions in 2022/23 with a primary diagnosis of urinary tract infection (UTI). Among these cases, individuals over the age of 65 represented 56%, totaling 82,392 admissions, with the highest number of cases occurring in the 80-84 age group (17,280 cases). This increasing prevalence of urinary disorders is driving the growth of the urinary retention drug market.
Key players in the urinary retention drug market are focusing on the development of innovative formulations such as extended-release tablets to improve patient compliance and offer prolonged symptom relief. Extended-release (ER) tablets are designed to release the active ingredient gradually over time, maintaining a consistent drug concentration in the bloodstream and reducing the need for frequent dosing compared to immediate-release tablets. For instance, in April 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder (OAB). Mirabegron, a selective beta-3 adrenergic agonist, relaxes bladder muscles to reduce urinary urgency, frequency, and incontinence. Although primarily used for OAB, it can also assist in managing urinary retention linked to overactive bladder conditions. The medication is administered as a once-daily oral dose.
In November 2024, Boston Scientific Corporation, a healthcare company based in the U.S., acquired Axonics Inc. for $3.3 billion. This acquisition allows Boston Scientific to expand its urology portfolio by integrating innovative technologies that address urinary and bowel dysfunction. Axonics Inc., a medical technology company based in the U.S., specializes in sacral neuromodulation (SNM) therapy for urinary control. This therapy is used to treat urinary retention and the symptoms of overactive bladder.
Major players in the urinary retention drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., and UroGen Pharma Ltd.
North America was the largest region in the urinary retention drug market in 2024. The regions covered in urinary retention drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the urinary retention drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The urinary retention drugs market consist of sales of tamsulosin (flomax), bethanechol (urecholine), terazosin (hytrin), doxazosin (cardura), finasteride (proscar), and alfuzosin (uroxatral). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Urinary Retention Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on urinary retention drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for urinary retention drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Alpha Blockers; Beta-3 Agonists; Anticholinergics; Surgical Agents
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Urinary Retention Drug Market Characteristics
3. Urinary Retention Drug Market Trends And Strategies
4. Urinary Retention Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Urinary Retention Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Urinary Retention Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Urinary Retention Drug Market Growth Rate Analysis
5.4. Global Urinary Retention Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Urinary Retention Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Urinary Retention Drug Total Addressable Market (TAM)
6. Urinary Retention Drug Market Segmentation
6.1. Global Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alpha Blockers
Beta-3 Agonists
Anticholinergics
Surgical Agents
6.2. Global Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Urinary Retention
Postoperative Urinary Retention
Neurogenic Bladder
6.3. Global Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Transdermal
6.4. Global Urinary Retention Drug Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.5. Global Urinary Retention Drug Market, Sub-Segmentation Of Alpha Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alpha-1 Blockers
Alpha-2 Blockers
6.6. Global Urinary Retention Drug Market, Sub-Segmentation Of Beta-3 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Beta-3 Agonists
6.7. Global Urinary Retention Drug Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antimuscarinics
Non-Selective Anticholinergics
6.8. Global Urinary Retention Drug Market, Sub-Segmentation Of Surgical Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anesthetics
Hemostatic Agents
Muscle Relaxants
Antibiotic Prophylaxis
7. Urinary Retention Drug Market Regional And Country Analysis
7.1. Global Urinary Retention Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Urinary Retention Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Urinary Retention Drug Market
8.1. Asia-Pacific Urinary Retention Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Urinary Retention Drug Market
9.1. China Urinary Retention Drug Market Overview
9.2. China Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Urinary Retention Drug Market
10.1. India Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Urinary Retention Drug Market
11.1. Japan Urinary Retention Drug Market Overview
11.2. Japan Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Urinary Retention Drug Market
12.1. Australia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Urinary Retention Drug Market
13.1. Indonesia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Urinary Retention Drug Market
14.1. South Korea Urinary Retention Drug Market Overview
14.2. South Korea Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Urinary Retention Drug Market
15.1. Western Europe Urinary Retention Drug Market Overview
15.2. Western Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Urinary Retention Drug Market
16.1. UK Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Urinary Retention Drug Market
17.1. Germany Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Urinary Retention Drug Market
18.1. France Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Urinary Retention Drug Market
19.1. Italy Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Urinary Retention Drug Market
20.1. Spain Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Urinary Retention Drug Market
21.1. Eastern Europe Urinary Retention Drug Market Overview
21.2. Eastern Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Urinary Retention Drug Market
22.1. Russia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Urinary Retention Drug Market
23.1. North America Urinary Retention Drug Market Overview
23.2. North America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Urinary Retention Drug Market
24.1. USA Urinary Retention Drug Market Overview
24.2. USA Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Urinary Retention Drug Market
25.1. Canada Urinary Retention Drug Market Overview
25.2. Canada Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Urinary Retention Drug Market
26.1. South America Urinary Retention Drug Market Overview
26.2. South America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Urinary Retention Drug Market
27.1. Brazil Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Urinary Retention Drug Market
28.1. Middle East Urinary Retention Drug Market Overview
28.2. Middle East Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Urinary Retention Drug Market
29.1. Africa Urinary Retention Drug Market Overview
29.2. Africa Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Urinary Retention Drug Market Competitive Landscape And Company Profiles
30.1. Urinary Retention Drug Market Competitive Landscape
30.2. Urinary Retention Drug Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Urinary Retention Drug Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. Novartis International AG
31.4. GlaxoSmithKline plc
31.5. Medtronic plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Teva Pharmaceutical Industries Limited
31.9. Boehringer Ingelheim International GmbH
31.10. Astellas Pharma Inc.
31.11. Sun Pharmaceutical Industries Limited
31.12. Aurobindo Pharma Limited
31.13. Lupin Limited
31.14. Cadila Healthcare Limited
31.15. Torrent Pharmaceuticals Limited
32. Global Urinary Retention Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Urinary Retention Drug Market
34. Recent Developments In The Urinary Retention Drug Market
35. Urinary Retention Drug Market High Potential Countries, Segments and Strategies
35.1 Urinary Retention Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Urinary Retention Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Urinary Retention Drug Market In 2029 - Growth Strategies
